Literature DB >> 1417515

Humoral and cellular immunologic study of cerebrospinal fluid in a patient with Behçet encephalitis.

P J Jongen1, H E Daelmans, B Bruneel, M R den Hartog.   

Abstract

To study the immunopathogenesis of neuro-Behçet syndrome, we performed serial cerebrospinal fluid (CSF) examinations in a patient with Behçet's syndrome and involvement of the central nervous system. Before and after immunosuppressive treatment, we measured the CSF indexes of immunoglobulins (Ig), and the third (C3) and the fourth (C4) component of complement, and quantified immune complexes and lymphocyte subsets in CSF and peripheral blood. During active encephalitis, humoral abnormalities were intrathecal production of IgM and, to a lesser degree, IgG and IgA, presence of immune complexes in CSF but not in peripheral blood, intrathecal C3 production, and elevated CSF C3 and C4 concentrations; lymphocyte subset analysis showed an increased CSF CD8+ T-cell percentage, in combination with slightly increased PB CD3+ and CD8+ T-cell subsets. After effective immunosuppressive treatment, humoral and cellular CSF values were normal. We conclude that intrathecally produced immunoglobulins, immune complexes, and C3 as well as CD8+ T cells are likely to participate in the development of Behçet encephalitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417515     DOI: 10.1001/archneur.1992.00530340101024

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  2 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Parenchymal neuro-Behçet disease with erectile dysfunction and micturition disturbances: case report and literature review.

Authors:  Ali Taylan; Merih Birlik
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.